Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
10 results
  • Lung Cancer, Head and Neck Cancer, Sarcoma, Kidney Cancer, Cervical Cancer

19-090          Phase I

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms (View details on

  • Breast Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Merkel Cell Carcinoma

18-051          Phase I

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors (View details on

  • Kidney Cancer

17-492          Phase I

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (View details on

  • Kidney Cancer

17-084          Phase II

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC) (View details on

  • Kidney Cancer

19-257          Phase III

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (View details on

  • Kidney Cancer

20-236          Phase I

An Open-label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors (View details on

  • Kidney Cancer

17-704          Phase III

ECOG-ACRIN EA8143, A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (View details on

  • Bladder Cancer, Prostate Cancer, Lung Cancer, Melanoma, Kidney Cancer, Breast Cancer

16-150          Phase I

Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (View details on

Showing 1 - 10 of 10 results